Arch Physiol Biochem
Labs are not routinely required unless clinically necessary
To our surprise, for several of these subcategories exenatide and sitagliptin apparently significantly reduced the odds ratios, in the case of exenatide, for example, regarding lung cancer, prostate cancer, lymphoma/multiple myeloma, metastasising tumors of unknown origin, and other tumours not specified. Sitagliptin significantly reduced the odds ratios for colon cancer, prostate cancer, and other tumours not specified. On the other hand, with exenatide treatment the rate of reporting carcinoid and stromal tumors and tumors of the female genital tract was apparently significantly elevated, and with sitagliptin treatment leukemias appeared to be reported significantly more often
These additional metrics can show progress even when the scale seems stuck, especially during the natural plateaus that often occur with GLP-1 therapy
In the U.S., retail pharmacies often lose $10 to $40 per script filled because Pharmacy Benefit Manager (PBM) reimbursements fall below the wholesale acquisition cost
